共 50 条
- [1] The characteristics of long-lasting responders to PD-1 inhibitor in advanced non-small cell lung cancer patientsANNALS OF ONCOLOGY, 2019, 30Jo, H.Yoshida, T.Yagishita, S.Shinno, Y.Okuma, Y.Goto, Y.Horinouchi, H.Yamamoto, N.Ohe, Y.
- [2] Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 137 - 137Thomas, M.Kohlhaeufl, M.Reck, M.Engel-Riedel, W.Kortsik, C.Bullinger, L.Schneider, C. -P.Felip, E.Brahmer, J.Vokes, E.Gettinger, S.Geese, W.Yoon, D.Healey, D.Li, A.Eberhardt, W. E. E.
- [3] Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patientsCANCER RESEARCH, 2015, 75Kamphorst, Alice O.Pillai, Rathi N.Yang, ShuAkondy, RamaKoenig, LydiaYu, KeMcCausland, MeganSica, GabrielKhuri, Fadlo R.Owonikoko, Taofeek K.Ramalingam, Suresh S.Ahmed, Rafi
- [4] Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Spieler, Benjamin OrenLopes, GilbertoDal Pra, AlanDiwanji, TejanYechieli, RaphaelFreedman, Laura M.Mihaylov, Ivaylo
- [5] Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using NivolumabONCOLOGY LETTERS, 2020, 19 (02) : 1559 - 1566Nardone, ValerioTini, PaoloPastina, PierpaoloBotta, CirinoReginelli, AlfonsoCarbone, Salvatore FrancescoGiannicola, RoccoCalabrese, GraziaTebala, CarmelaGuida, CesareGiudice, AldoBarbieri, VitoTassone, PierfrancescoTagliaferri, PierosandroCappabianca, SalvatoreCapasso, RosannaLuce, AmaliaCaraglia, MicheleMazzei, Maria AntoniettaPirtoli, LuigiCorreale, Pierpaolo
- [6] PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)Discover Oncology, 16 (1)Samaneh MoradiPedram SarikhaniRafid Jihad AlbadrWaam Mohammed TaherMariem AlwanMahmood Jasem JawadHiba MushtaqNiyousha Vakilzadehian
- [7] ACQUIRED RESISTANCE TO PD-(L)1 BLOCKADE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A553 - A554Ricciuti, BiagioLamberti, GiuseppeAlessi, Joao VictorPecci, FedericaDi Federico, AlessandroWang, XinanBarrichello, AdrianaVaz, VictorPangilinan, AndyHaradon, DanielleElinton, LeeNishino, MizukiRodig, ScottSholl, LynetteAwad, Mark
- [8] Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Ricciuti, BiagioAlessi, Joao Victor MachadoLi, Yvonne Y.Vaz, Victor R.Pecci, FedericaLamberti, Giuseppede Castro Barrichello, Adriana PaulaGupta, HershNishino, MizukiCherniack, Andrew D.Sholl, Lynette M.Rodig, Scott J.Awad, Mark M.
- [9] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung CancerCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683Bagley, Stephen J.Bauml, Joshua M.Langer, Corey J.
- [10] Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancerMOLECULAR ONCOLOGY, 2021, 15 (04) : 887 - 900Frigola, JoanNavarro, AlejandroCarbonell, CaterinaCallejo, AnaIranzo, PatriciaCedres, SusanaMartinez-Marti, AlexPardo, NuriaSaoudi-Gonzalez, NadiaMartinez, DeboraJimenez, JoseSansano, IreneMancuso, Francesco M.Nuciforo, PaoloMontuenga, Luis M.Sanchez-Cespedes, MontsePrat, AleixVivancos, AnaFelip, EnriquetaAmat, Ramon